AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04561921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study NCT03184220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid
Study NCT03184220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
Study NCT04561921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine-Levonordefrin Hydrochloride
Description: patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study NCT04357990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viruxal Oral and Nasal Spray
Description: Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
Study NCT04357990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a similar spray containing saline only.
Study NCT01475253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Releasing Intravesical System - LiRIS®
Description: Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
Study NCT01475253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LiRIS Placebo
Description: LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
Study NCT01475253 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Cystoscopy Procedure
Description: Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
Study NCT01129453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine
Description: CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
Study NCT03763903 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D training
Description: Skills (FLS tasks) training using 3D visualization
Study NCT03763903 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2D training
Description: Skills (FLS tasks) training using 2D visualization
Study NCT01129453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
Study NCT02611063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: 100mg qd, 150mg qd, or 100mg bid
Study NCT01088438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextualization workshop
Description: A four-hour course on contextualization.
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg
Study NCT00378950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach to Goal (TTG)
Description: The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
Study NCT00378950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Intervention (BEI)
Description: The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
Study NCT01154959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
Study NCT01154959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
Study NCT00041938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 325 mg per day
Study NCT00041938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: INR 2.5-3.0; target INR 2.75
Study NCT06235424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Del Nido Cardioplegia Solution
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
Study NCT06235424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTK solution
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
Study NCT04368312 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, just of questionnaire including validated tests
Study NCT03635151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Assessment and Skill-Building Kit (TASK III) Group
Description: The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
Study NCT03635151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support and Referral (ISR) Group
Description: The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg
Study NCT04478942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Product
Description: Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.
Study NCT04478942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Oxytocin
Description: Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
Study NCT02045810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Study NCT02045810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT02045810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02045810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02493140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cashew apple extract (Cashewin)
Description: 6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
Study NCT02493140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
Study NCT01468883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M
Description: Modified radical mastectomy
Study NCT01468883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X
Description: Excisional biopsy plus radiation
Study NCT03750617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-endoscopic screening risk assessment
Description: pre-endoscopic screening risk assessment
Study NCT01887665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives
Description: A structured system of prize-based financial incentives rewards attendance at treatment visits.
Study NCT00654017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator to be given per protocol.
Study NCT00654017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
Study NCT00667875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00667875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (25mg or 50 mg per titration schedule)
Study NCT00667875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone + Aripiprazole
Description: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
Study NCT05600452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
Study NCT05600452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat acclimation
Description: Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
Study NCT03824730 — intervention group
Intervention type: DEVICE
Intervention: Stenting of the Common and/or External Iliac Arteries
Description: Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries.
Study NCT01576107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise counseling (behavior change techniques)
Description: 4-week exercise intervention for cancer patients of different entities and out-patient regimes.
Study NCT01576107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress-management training
Description: 4-week stress-management-training for cancer patients of different entities and out-patient regimes.
Study NCT02622984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBIRT
Description: Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
Study NCT02622984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: Face to face standard intervention considered treatment as usual.
Study NCT03429972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elasto-Gel™
Description: Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
Study NCT03429972 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
Study NCT03429972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
Study NCT01771731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Study NCT01771731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Study NCT01747486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
Study NCT01877343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVInsight(TM)
Description: Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
Study NCT01726842 — intervention group
Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study NCT01347892 — intervention group
Intervention type: OTHER
Intervention: DeNovo NT Natural Tissue Graft
Description: DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
Study NCT03335579 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil
Description: Different combination of opioids and anesthetics
Study NCT00511446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, oxaliplatin, capecitabine
Description: Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03777488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms
Study NCT03655236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: low dose, orally, once-daily
Study NCT03655236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: high dose, orally, once-daily
Study NCT03655236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, orally, once-daily
Study NCT02055443 — intervention group
Intervention type: OTHER
Intervention: 12-lead holter monitor application
Description: -- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan.
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: cisatracurium 0.15mg/kg intravenously
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg
Study NCT03777488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonspecific Neuromuscular Blockade reversal
Description: neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific Neuromuscular Blockade reversal
Description: Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintaining the depth of neuromuscular blockade - rocuronium
Description: repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
Study NCT02546843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintaining the depth of neuromuscular blockade - cisatracurium
Description: repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
Study NCT06196021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular hyaluronic acid injection
Description: Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid.
Study NCT06196021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular hyaluronic acid injection
Description: Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid.
Study NCT04729647 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mastectomy
Description: Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)